HB 1533 (the Crown and Care Act) bans 12 specific harmful ingredients - including certain phthalates, formaldehyde, mercury, and PFAS chemicals - from cosmetic products sold in Maryland. It directly affects cosmetic manufacturers, retailers, and salons by prohibiting the sale or distribution of products containing these ingredients, with limited exceptions for unavoidable trace amounts from manufacturing processes. The bill authorizes the Maryland Department of Health to investigate complaints, inspect businesses, and enforce penalties, while allowing consumers harmed by violations to seek civil damages and attorney fees. This law aims to protect public health by reducing exposure to chemicals linked to health risks like skin irritation and potential long-term harm.
HB 1192 expands Maryland's State Board of Sign Language Interpreters from 7 to 11 members, requiring specific representation including deaf individuals, deafblind people, licensed interpreters from various settings (medical, legal, educational), and agency owners. The bill delays the deadline for the Board to establish licensing requirements from July 1, 2024, to December 31, 2026, and sets new rules for member removal if they miss meetings, fail to meet qualifications, or commit misconduct. Sign language interpreters in Maryland who provide services in the state will be directly affected by the updated licensing requirements and the Board's new structure. The bill also mandates that appointed members reflect Maryland's racial and geographic diversity where practicable.
SB 645 restructures Maryland's State Board of Sign Language Interpreters by expanding its membership from seven to 11 members with specific representation requirements, including a deafblind individual, deaf community members, licensed interpreters from various settings (legal, medical, educational), and ex-officio members from disability and labor agencies. The bill requires the Board to establish licensing requirements for sign language interpreters by December 31, 2026 (previously July 1, 2024), and mandates interpreters to meet these standards by that date. It also adds new grounds for the Governor to remove board members, including two consecutive unexcused absences or failing to attend 50% of meetings annually. These changes aim to improve board diversity, clarify licensing timelines, and ensure board members meet ongoing eligibility criteria.
SB 656 bans 12 specific harmful chemicals in cosmetics sold in Maryland, including formaldehyde, mercury, and certain PFAS chemicals. It creates civil liability for manufacturers or sellers who violate this ban, allowing consumers to sue for damages. The Maryland Department of Health gains authority to investigate complaints, inspect businesses, and collect product samples. The law exempts trace amounts of banned ingredients that occur unavoidably during manufacturing. The bill takes effect July 1, 2026.
HB 1135 allows pharmacists in Maryland to order certain vaccinations for patients aged 3 and older without needing to administer the vaccine themselves. Pharmacists must complete 20+ hours of approved training covering vaccine safety, injection techniques, and emergency response, hold current CPR certification, and report all vaccinations to the ImmuNet program. The bill specifically covers influenza, COVID-19, and emergency-use vaccines, and requires pharmacists to refer minors to pediatric care when ordering vaccines. This expands pharmacists' role in vaccine access while maintaining safety protocols and reporting requirements.
SB 773 allows pharmacists in Maryland to order certain vaccinations (like flu, COVID-19, or emergency vaccines) for patients aged 3 and older without needing to administer the vaccine themselves. To qualify, pharmacists must complete 20 hours of approved training, hold current CPR certification, and complete 2 hours of continuing education on immunizations. The bill requires pharmacists to follow written vaccine-specific protocols, report all vaccinations to Maryland’s ImmuNet registry, and refer pediatric patients to primary care providers when appropriate. This policy directly affects pharmacists, patients seeking these vaccines, and healthcare coordination for immunizations. The changes take effect October 1, 2026.
SB 915 requires individuals performing limited X-ray procedures (such as chest, spine, and limb imaging) in Maryland to register with the State Board of Physicians. It restricts these operations to non-invasive X-rays only (excluding CT scans, mammography, or fluoroscopy) and mandates 115 hours of specialized training plus 6 months of clinical experience. The bill also establishes disciplinary procedures for violations and allows physician assistants to perform X-ray duties under physician supervision, while updating rules for cardiovascular specialists and medical graduates. This directly affects medical staff, radiologic technicians, and physician assistants conducting basic X-ray services in clinical settings.
SB 778 creates a new "clinical research pharmacy permit" required for pharmacies conducting clinical trials in Maryland. It allows healthcare providers to own such pharmacies under specific conditions, including requiring a licensed pharmacist to be on-site at all times and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations from being classified as "practice of medicine," removing a licensing barrier for these activities. This directly affects pharmacies seeking to operate clinical trials, healthcare providers considering ownership, and the State Board of Pharmacy (as the permit issuer).
SB 159 requires Maryland's Emergency Medical Services (EMS) providers to maintain specific equipment and supplies on ambulances, including neonatal care items, and mandates quarterly reviews of performance data like response times and service quality. It also requires counties to establish formal, accessible complaint systems for ambulance quality or conduct issues, with online and in-person filing, tracking, and quarterly reporting to the state EMS Institute. These provisions directly affect all counties and municipalities operating or contracting EMS services, as well as the Maryland Institute for EMS Systems, which coordinates the statewide standards. The bill aims to standardize ambulance equipment, improve accountability through data reviews, and enhance patient access to complaint resolution. It takes effect July 1, 2026.
HB 347 adds hypertension to the list of occupational diseases presumed work-related for specific emergency responders in Maryland. It creates a legal presumption that firefighters, firefighting instructors, rescue squad members, advanced life support unit members, and State Fire Marshal staff with hypertension are entitled to workers' compensation benefits if they meet four conditions: diagnosed by a provider, prescribed hypertension medication for 90+ consecutive days, completed 2+ years of cumulative service in the state, and are currently employed in that role. This bill modifies Maryland’s workers’ compensation law (specifically Sections 9-502 and 9-503) to expand eligibility for these occupations without requiring separate proof that hypertension resulted from their job duties. It directly affects these emergency personnel seeking compensation for hypertension-related disability or death.
